School of Medicine
Showing 1-20 of 25 Results
-
Lynn C. Waelde, Ph.D.
Adjunct Clinical Professor, Psychiatry and Behavioral Sciences
BioLynn C. Waelde, Ph.D. is an Adjunct Clinical Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine and Professor Emeritus in the Psychology Department at Palo Alto University. Dr. Waelde’s many collaborative publications address the impacts of traumatic events and ways to use mindfulness and meditation to promote resilience and recovery from stress and trauma. She founded and directed the Inner Resources Center which offered intervention groups and trainings to thousands of participants, clients, and therapists over the past 15 years. Dr. Waelde is the author of Mindfulness and Meditation in Trauma Treatment: The Inner Resources for Stress Program, published in 2022. She has taken a special interest in family caregivers and the Inner Resources for Stress program has been named a Best Practice by the Benjamin Rose Institute on Aging. She recently coauthored Family Caregiver Distress, which is forthcoming in 2023. She is on the editorial board of Journal of Traumatic Stress and an Associate Editor of Mindfulness.
-
Dennis Wall
Professor of Pediatrics (Clinical Informatics), of Biomedical Data Science and, by courtesy, of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsSystems biology for design of clinical solutions that detect and treat disease
-
Gordon Wang
Clinical Associate Professor, Psychiatry and Behavioral Sciences
BioGordon Wang received his Bachelors of Arts and Science from the University of California, Davis in 2000 majoring in Comparative literature and Genetics. He received her PhD under Dr. Mu-ming Poo at the University of California, Berkeley in 2005 studying the role of ion channels in mediating neuronal growthcone guidance decisions. As a postdoctoral scholar in the lab of Dr. Stephen Smith at Stanford University, Gordon developed a computational architecture for the detailed study of molecular diversity in synapses and using this system, he studied the diverse role of synaptic diversity in neurodevelopmental diseases, such as fragile x syndrome. In a co-postdoc in Dr. Philippe Mourrain's lab, he studied the dynamic plasticity of synapses in sleep and circadian cycles in larval zebrafish using multi-photon microscopy. The Wang lab focuses on further developing imaging tools to the deep analysis of proteins, mRNA and lipids at the synapses, and understanding how synaptic heterogeneity affect the function of neural circuits throughout development and aging and in diseases such as autism and fragile x syndrome.
-
Po Wang
Clinical Professor, Psychiatry and Behavioral Sciences
Clinical Professor, Psychiatry and Behavioral SciencesCurrent Research and Scholarly InterestsBipolar Disorders, Psychopharmacology, Treatment, Anticonvulsants, Mood stabilizers
-
Kathleen Watson
Instructor, Psychiatry and Behavioral Sciences
BioKathleen Watson, Ph.D., currently serves as an instructor at Stanford University School of Medicine, specializing in Epidemiology and Clinical Research. She co-founded Microclinic International in 2007, where she served as Chief Operating Officer until 2012, focusing on socially-based health interventions for underserved communities.
Dr. Watson's research encompasses various aspects of mental health and metabolism. She investigates the connection between insulin resistance and depression, using computational psychiatry to uncover insights into the interplay of metabolic factors in mental well-being. Additionally, her exploration of cognitive aging examines how metabolic alterations might impact cognitive decline and related disorders. Furthermore, her research in proteomics aims to identify potential biomarkers for severe major depressive disorder. Dr. Watson has recently become a part of the Stanford Autism Center for Excellence Data Core, where she works under the guidance of Dr. Booil Jo. -
Aileen Whyte
Clinical Associate Professor, Psychiatry and Behavioral Sciences - Child & Adolescent Psychiatry and Child Development
BioDr. Aileen Whyte, a licensed psychologist in California, brings over two decades of specialized expertise to the treatment of eating disorders in young people. Beyond her clinical practice, Dr. Whyte actively works on implementing strategies to expand the reach of evidence-based treatments for eating disorders, aiming to make these best-practice interventions more accessible to a wider population.
Dr Whyte serves as the Director of the Stanford Outpatient Child & Adolescent Eating Disorders Clinic, where she provides treatment to young people with eating disorders and provides supervision to psychology and psychiatry fellows. Dr Whyte is a certified practitioner and consultant in Family-Based Treatment (FBT) for eating disorders. She serves as a study therapist in NIMH-sponsored randomized clinical trials focused on examining FBT and related adaptations.
In addition to her clinical responsibilities, Dr. Whyte has led multiple seminars, workshops, and training sessions dedicated to the treatment of eating disorders. She provides ongoing training and consultation in FBT, reaching diverse audiences, including multidisciplinary clinicians, psychologists, and psychiatrists, within the US and internationally.
Dr. Whyte earned her PhD in Clinical Psychology from the New School for Social Research in New York. Her research and clinical interests converge on the implementation and dissemination of evidence-based treatments for eating disorders. -
Leanne Williams
Vincent V.C. Woo Professor, Professor of Psychiatry and Behavioral Sciences (Major Laboratories and Clinical Translational Neurosciences Incubator) and, by courtesy, of Psychology
Current Research and Scholarly InterestsA revolution is under way in psychiatry. We can now understand mental illness as an expression of underlying brain circuit disruptions, shaped by experience and genetics. Our lab is defining precision brain circuit biotypes for depression, anxiety and related disorders. We integrate large amounts of brain imaging, behavioral and clinical data and computational approaches. Biotypes are used in personalized intervention studies with selective drugs, neuromodulation and exploratory therapeutics.
-
Nolan Williams
Associate Professor of Psychiatry and Behavioral Sciences (Major Laboratories & Clinical Translational Neurosciences Incubator) and, by courtesy, of Radiology (Neuroimaging and Neurointervention)
BioNolan Williams, M.D. is an Associate Professor of Psychiatry and Behavioral Sciences at Stanford University and Director of the Stanford Brain Stimulation Lab. The long-term goals of his research program are to develop innovative technologies and therapeutics capable of modulating the neural circuitry disrupted in mood disorders, OCD, and other neuropsychiatric conditions. His team has been developing neuroimaging-based approaches to precisely target therapeutic delivery and predict treatment responses to therapeutic neuromodulation and psychedelics. Dr. Williams earned his M.D. and completed his dual residencies in neurology and psychiatry at the Medical University of South Carolina (MUSC). Triple board-certified in general neurology, general psychiatry, as well as behavioral neurology and neuropsychiatry, Dr. Williams brings a comprehensive background in clinical neuroscience to his role as a clinically active neuropsychiatrist. His expertise extends to the development and implementation of novel therapeutics, including devices and novel compounds, for central nervous system illnesses.
Over the past decade, Dr. Williams’ laboratory alongside collaborators at Stanford University have pioneered multiple novel therapeutic and human neuroscience approaches. Notably, Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) is the world's first non-invasive, rapid-acting neuromodulation approach for treatment-resistant depression. SAINT received FDA Breakthrough Device Designation Status (2021) and FDA Clearance (2022) and is the first psychiatric treatment to be covered by Medicare New Technology Add-On Payment (NTAP). As of April 2024, SAINT has been reimbursed for patients suffering from severe depression within inpatient psychiatric units. The SAINT technology is being deployed both clinically and in research protocols in laboratories and hospitals worldwide. Dr. Williams also has an expertise in psychedelic medicines for neuropsychiatric illness and is the first investigator to conduct mechanistic clinical trials exploring the neurobiological effects of ibogaine.
His research accomplishments have garnered international recognition, earning prestigious awards from the Pritzker Neuropsychiatric Disorders Consortium, One Mind Institute, Wellcome Leap Foundation, International Brain Stimulation Conference, National Institute of Mental Health (Biobehavioral Research Award for Innovative New Scientists), Society of Biological Psychiatry (A. E. Bennett Award), along with multiple awards from the Brain Behavior Research Foundation (most notably the Gerald L. Klerman Award). His work has been featured in Scientific American, The New York Times, The Washington Post, USA Today, CBS Sunday Morning, and the TODAY Show. -
Sharon E. Williams PhD
Clinical Professor, Psychiatry and Behavioral Sciences - Child & Adolescent Psychiatry and Child Development
Current Research and Scholarly InterestsDr. Williams work focuses primarily on cognitive and emotional recovery of children who have been medically compromised. With improved medical treatment and increased survival rates comes the need to better understand the challenges that patients face following a life threatening illness or injury. Dr. Williams utilizes neuropsychological assessments to understand the cognitive abilities of children who have been diagnosed with cancer, head injuries, genetic disorders and other medical conditions.
